Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P11177
UPID:
ODPB_HUMAN
Alternative names:
-
Alternative UPACC:
P11177; B2R7L0; B4DDD7; Q6FH45; Q9BQ27; Q9UFK3
Background:
The Pyruvate dehydrogenase E1 component subunit beta, mitochondrial, encoded by the P11177 gene, plays a pivotal role in cellular energy metabolism. It facilitates the conversion of pyruvate to acetyl-CoA and CO2, bridging the glycolytic pathway with the tricarboxylic cycle, essential for ATP production.
Therapeutic significance:
Pyruvate dehydrogenase E1-beta deficiency, a disease linked to this protein, manifests as primary lactic acidosis in children, with symptoms ranging from fatal lactic acidosis in newborns to chronic neurological dysfunction. Understanding the role of this protein could lead to novel therapeutic strategies for managing this condition.